Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
230 studies found for:    "thrombotic thrombocytopenic purpura" OR "Purpura, Thrombocytopenic"
Show Display Options
RSS Create an RSS feed from your search for:
"thrombotic thrombocytopenic purpura" OR "Purpura, Thrombocytopenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Drug: Danazol
2 Completed ADAMTS13 in Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention:
3 Withdrawn Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Drug: Rituximab
4 Completed Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Drug: rituximab
5 Active, not recruiting Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Drug: Cyclosporine;   Drug: Prednisone
6 Completed Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody;   Biological: Placebo;   Other: Plasma exchange
7 Recruiting Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Condition: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Biological: caplacizumab;   Biological: placebo
8 Unknown  The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura (TTP)
Intervention: Drug: Rituximab
9 Terminated Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: Biological: Uniplas;   Biological: Cryosupernatant plasma
10 Completed Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Intervention: Drug: Recombinant ADAMTS13
11 Recruiting Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Biological: rituximab
12 Not yet recruiting Octaplas Adult TTP Trial
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: Octaplas;   Drug: Standard Plasma
13 Terminated
Has Results
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Drug: Rituximab;   Procedure: Plasma exchange;   Drug: Corticosteroids
14 Recruiting Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Conditions: Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
Intervention: Other: Observation
15 Unknown  Rituximab in Patients With Relapsed or Refractory TTP-HUS
Conditions: Thrombotic Thrombocytopenic Purpura;   Hemolytic Uremic Syndrome
Intervention: Drug: Rituximab
16 Recruiting A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Eltrombopag Tablets;   Drug: Eltrombopag PfOS
17 Completed
Has Results
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Fostamatinib Disodium / R935788
18 Completed Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Rituximab;   Drug: Placebo
19 Completed
Has Results
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
Condition: Purpura, Thrombocytopaenic, Idiopathic
Intervention: Drug: eltrombopag
20 Completed
Has Results
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopaenic, Idiopathic
Intervention: Drug: Eltrombopag olamine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.